FJFuquan Jiang

Fuquan Jiang

*This is an algorithmically generated author record based on publicly available information.

Fuquan Jiang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Xinquan Gu

    Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, China.

    2 shared publications
  • Bo Li

    State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China

    1 shared publication
  • Fan Wang

    State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China

    1 shared publication
  • Jiansong Han

    Department of Urology, China-Japan Union Hospital of Jilin University, Changchun, China

    1 shared publication
  • Jingjing Li

    State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun 130022, China

    1 shared publication
  • Kai Liu

    Engineering Research Center of Advanced Rare Earth Materials (Ministry of Education) Department of Chemistry Tsinghua University Beijing China

    1 shared publication

Latest Publications

  • Open Access

    Long-Lasting Proteinaceous Nanoformulation for Tumor Imaging and Therapy

    by Lai Zhao, Xinquan Gu, Fuquan Jiang, Bo Li, Shuang Lu, Fan Wang, Yao Sun, Kai Liu, Jingjing Li

    Nanodrugs have attracted increasing interest in drug delivery and disease treatment. However, the cumbersome preparation process and the poor biocompatibility of nanodrugs obstruct their clinical translation. In this study, we utilized a self-assembly strategy to develop a low-toxicity, long-lasting nanodrug for the effective treatment and real-time monitoring of bladder tumors. The accurate self-assembly of compatible raw materials allowed for an encapsulation rate of 43.7% for insoluble erdafitinib. Interestingly, robust therapeutic effects and reduced side effects could be realized simultaneously using this nanodrug, enabling broader scenarios for the clinical application of erdafitinib. Furthermore, the nanodrug exhibited a significantly prolonged in vivo half-life (14.4 h) and increased bioavailability (8.0 mu g/mL & BULL;h), which were 8.3 times and 5.0 times higher than those of its nonformulated counterpart. Also, it is worth mentioning that the introduction of a fluorescent protein module into the nanodrug brought up a novel possibility for real-time feedback on the therapeutic response. In conclusion, this research revealed a versatile technique for developing low-toxicity, long-acting, and multifunctional nanoformulations, paving the way for multidimensional therapy of malignant tumors.